Although the initial aspiration for the assay was to provide a cost-effective, personalized approach to chemoendocrine prescription in ER+/HER2− early-stage breast cancer [10,11], novel data has emerged challenging this original perception, suggesting the true cost-effectiveness of the assay in clinical practice [12,13]. Here, ERBB2 is linked to breast cancer.